Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate ALX Oncology Holdings Inc. before investing.

In this article, we go over a few key elements for understanding ALX Oncology Holdings Inc.’s stock price such as:

• ALX Oncology Holdings Inc.’s current stock price and volume
• Why ALX Oncology Holdings Inc.’s stock price changed recently
• Upgrades and downgrades for ALXO from analysts
• ALXO’s stock price momentum as measured by its relative strength

About ALX Oncology Holdings Inc. (ALXO)

Before we jump into ALX Oncology Holdings Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Want to learn more about ALX Oncology Holdings Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about ALX Oncology Holdings Inc..

ALX Oncology Holdings Inc.’s Stock Price as of Market Close

As of April 21, 2026, 10:46 AM, CST, ALX Oncology Holdings Inc.’s stock price was $1.725.

ALX Oncology Holdings Inc. is down 1.43% from its previous closing price of $1.750.

During the last market session, ALX Oncology Holdings Inc.’s stock traded between $1.680 and $1.770. Currently, there are approximately 54.28 million shares outstanding for ALX Oncology Holdings Inc..

ALX Oncology Holdings Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

ALX Oncology Holdings Inc. Stock Price History

ALX Oncology Holdings Inc.’s (ALXO) price is currently down 13.97% so far this month.

During the month of April, ALX Oncology Holdings Inc.’s stock price has reached a high of $2.050 and a low of $1.600.

Over the last year, ALX Oncology Holdings Inc. has hit prices as high as $2.660 and as low as $0.404. Year to date, ALX Oncology Holdings Inc.’s stock is up 52.65%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused ALX Oncology Holdings Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 20, 2026, there were 0 analysts who downgraded ALX Oncology Holdings Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate ALX Oncology Holdings Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on ALX Oncology Holdings Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about ALX Oncology Holdings Inc. (ALXO) by visiting AAII Stock Evaluator.

Relative Price Strength of ALX Oncology Holdings Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 20, 2026, ALX Oncology Holdings Inc. has a weighted four-quarter relative price strength of 41.69%, which translates to a Momentum Score of 97 and is considered to be Very Strong.

Want to learn more about how ALX Oncology Holdings Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

ALX Oncology Holdings Inc. Stock Price: Bottom Line

As of April 21, 2026, ALX Oncology Holdings Inc.’s stock price is $1.725, which is down 1.43% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like ALX Oncology Holdings Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.